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ABSTRACT
Background As concerns about the prevalence of infections 
that are resistant to available antibiotics increase, attention 
has turned toward the use of these medicines both within and 
outside of formal healthcare settings. Much of what is known 
about use beyond formal settings is informed by survey- 
based research. Few studies to date have used comparative, 
mixed- methods approaches to render visible patterns of use 
within and between settings as well as wider points of context 
shaping these patterns.
Design This article analyses findings from mixed- methods 
anthropological studies of antibiotic use in a range of rural and 
urban settings in Zimbabwe, Malawi and Uganda between 
2018 and 2020. All used a ‘drug bag’ survey tool to capture 
the frequency and types of antibiotics used among 1811 
households. We then undertook observations and interviews in 
residential settings, with health providers and key stakeholders 
to better understand the stories behind the most- used 
antibiotics.
Results The most self- reported ‘frequently used’ antibiotics 
across settings were amoxicillin, cotrimoxazole and 
metronidazole. The stories behind their use varied between 
settings, reflecting differences in the configuration of health 
systems and antibiotic supplies. At the same time, these stories 
reveal cross- cutting features and omissions of contemporary 
global health programming that shape the contours of antibiotic 
(over)use at national and local levels.
Conclusions Our findings challenge the predominant focus 
of stewardship frameworks on the practices of antibiotic 
end users. We suggest future interventions could consider 
systems—rather than individuals—as stewards of antibiotics, 
reducing the need to rely on these medicines to fix other issues 
of inequity, productivity and security.
INTRODUCTION
To mitigate against the predicted health and 
economic impacts of antimicrobial resistance 
(AMR), the WHO’s global action plan has 
called for improved surveillance of antibiotic 
use to inform antimicrobial stewardship strat-
egies.1 Many low- income and middle- income 
countries (LMICs) have experienced steep 
rises in antibiotic use in recent decades2–6 
and been identified as particular targets for 
interventions. Surveillance at national level 
has been challenging to implement, and 
has generally prioritised the collection of 
Key questions
What is already known?
 ► Antimicrobial resistance is a key health challenge 
of our time, its rise attributed to widespread use of 
antibiotics.
 ► Capturing the volume, types and stories of antibiot-
ics used both within and outside formal prescriber 
settings is challenging but important to guide efforts 
to optimise antibiotic use.
 ► Existing survey research in low- and middle- income 
countries contributes to a behaviour- oriented agenda by 
pinpointing demographic and educational associations 
with antibiotic use.
What are the new findings?
 ► The most frequently used antibiotics among selected 
households in Malawi, Zimbabwe and Uganda were 
amoxicillin, cotrimoxazole and metronidazole.
 ► The reasons for varying antibiotic use profiles between 
and within countries reflected particular histories, sys-
tems and relations.
 ► Cross- cutting drivers of antibiotic use included gaps in 
public sector healthcare, the prominence of donor pro-
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aggregated consumption data from sales and imports, 
accompanied by limited hospital data, and even more 
limited information outside of hospitals on how antibi-
otics are actually used by different provider types and 
patients.7 A particular area of concern is antibiotic use 
beyond formal prescriber settings (retail pharmacies, 
drug shops, markets, households and farms), an under-
standing of which is crucial for producing a comprehen-
sive picture of antibiotic use in LMICs and for developing 
context- sensitive interventions, particularly in settings 
with large informal pharmaceutical markets.8 9 Such data, 
however, are more resource intensive to collect system-
atically than consumption and prescribing data and are 
made especially challenging by the fact that ‘antibiotic’ is 
a complex category with numerous classes and uses and 
does not translate well either linguistically or conceptu-
ally in many settings.10 11
A growing number of surveys, systematic reviews 
and meta- analyses have nonetheless begun to eluci-
date patterns and predictors of antibiotic use at the 
community level. Analyses of demographic and health 
surveys and multi- indicator cluster surveys suggest that 
the greatest rises in antibiotic use in LMICs have been 
among rural, the poorest and least educated popula-
tions, particularly in low- income countries and South- 
East Asia, although the greatest overall rates are seen in 
urban centres and among the most affluent and most 
educated demographics.3 12 Studies have further sought 
to capture the extent of the misuse of antibiotics, under-
girded by benchmarking ‘(ir)rational’ practice against 
indicators of expected clinical need. Findings indicate 
high rates of inappropriate use across LMICs,13–16 and 
that non- prescription use or ‘self- medication’ can make 
up as much as 100% in some populations.16 A recent 
study identified a greater prevalence of and reliance on 
informal providers in Asian countries than in African 
countries, with self- medication generally considered 
a cheaper, more convenient option than attending 
healthcare facilities,17 although this and other studies 
show many factors affect if/where treatment is sought, 
including policy and health system context, symptoms, 
disease severity, distance to travel, age of patient and 
trust in medicines and providers.3 13 14 18 Some studies 
have also broken down use profiles by antibiotic type 
and, increasingly, have mapped these onto the WHO’s 
Access, Watch, Reserve (AWaRe) classification system.19 
The majority of antibiotic use in LMICs appears to be 
predominated by substances in the Access group,13 17 20–23 
although use profiles vary considerably by setting and 
Watch group antibiotics appear to be more widely used 
in Asia than in Africa.17
While quantitative survey data are important for 
targeting interventions to particular populations, quali-
tative methods are vital for explaining antibiotic use in 
context.24 25 A strength of social research, including the 
observational techniques of ethnography, is the ability 
to capture, analyse and articulate the often taken- for- 
granted backdrops that shape—and are reproduced by—
the ways people live in the world. An expanding body of 
such research has demonstrated that many of the antibi-
otic use practices that would be considered ‘irrational’ 
from a biomedical perspective (eg, storing antibiotics 
for later, sharing them with others and using informal 
providers) are highly rational within the material and 
moral worlds inhabited by people living in contexts of 
scarcity and precarity.26–29 Anthropologists have shown 
that expectations for medicinal care and increasing reli-
ance on antibiotics are tied to processes of pharmaceu-
ticalisation that have disproportionately affected people 
living in LMICs, in which care has been progressively 
stripped to little more than the giving and receiving of 
medicines.26 30 31 The work of social scientists has contrib-
uted to a growing recognition of the wider structural 
processes shaping antibiotic use practices in LMICs and 
that these should be considered in stewardship strategies 
moving forward.32 33
In- depth qualitative approaches necessarily require 
a focus on particular sites and contexts. Few studies 
using such methods, however, have attempted the kind 
of multi- sited, comparative analyses more common in 
survey research to compare patterns of, and underlying 
reasons for, antibiotic use across different settings.17 18 
Such research that can build in the power of comparative 
approaches—that render visible what might otherwise 
be taken for granted in a given setting—can enhance 
the ability of social research to contribute to interven-
tions at multiple levels of scale. This article analyses 
findings from anthropological studies of household 
antibiotic use in Malawi, Uganda and Zimbabwe, which 
used mixed- methods research designs to capture, situate 
and compare the stories of antibiotics and their use in 
different settings. Our aim is both to increase under-
standing of patterns and reasons behind antibiotic use 
at community level and to contribute to ongoing debates 
around who or what should be considered antibiotic 




The data on which this article is based are drawn from 
anthropological research on antibiotic use in Malawi, 
Zimbabwe and Uganda, which took place within two 
projects—Febrile Illness Evaluation in a Broad Range 
Key questions
What do the new findings imply?
 ► Research foregrounding individual characteristics and behaviour 
risks overlooking structural and systemic reasons for antibiotic use.
 ► There is a need to consider systems - rather than individuals - as 
stewards of antibiotics ifsafe, sustainable reductions in antibiotic 
use are to be achieved within and beyond prescriber settings.
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of Endemicities (FIEBRE) and Antimicrobials in Society 
(AMIS)—between April 2018 and December 2020. The 
concept for this cross- site paper emerged during the 
analysis phase of both projects in late 2019. The multi-
disciplinary FIEBRE and AMIS teams were comprised 
of social scientists (mostly anthropologists), epidemiolo-
gists, clinical and laboratory scientists, pharmacists, post-
graduate students, research assistants, project managers 
and administrators.
Malawi, Zimbabwe and Uganda are postcolonial states 
in sub- Saharan Africa with different historical relation-
ships with biomedicine and antibiotics,34 but all have 
high rates of poverty, inequality and donor- dependent 
health systems. FIEBRE sites (Chikwawa District, Malawi, 
and suburbs of Harare, Zimbabwe) were selected to 
evaluate febrile illness in malaria- endemic and non- 
endemic settings, while AMIS sites (Kampala and Tororo 
District, Uganda) were selected purposively to compare 
urban and rural antibiotic use (figure 1). FIEBRE and 
AMIS focused on low- income residential areas, but there 
was also considerable heterogeneity between sites that 
enables comparison between a range of different urban 
and rural environments, health system contexts and 
degrees of poverty (table 1).
Household surveys
Data collection commenced with six household surveys, 
including two in each country (see table 2). In the FIEBRE 
settings (Zimbabwe and Malawi), the selection of house-
holds in the two larger surveys (ZU1 and MR1) followed 
the eligibility criteria for study’s clinical protocol. Specif-
ically, community ‘controls’, matched by age, sex and 
residential proximity to patient cases attending outpa-
tient facilities with febrile illness, were identified and 
invited to take part in the study. A survey of antibiotic 
use practices was conducted during the same visit as for 
the clinical activities among consenting households. The 
smaller, purposively sampled surveys (ZU2 and MR2) were 
conducted to include households in geographical areas 
of relevance to antibiotic use not captured in the larger 
surveys, which in ZU2 included a suburb with known 
informal markets for antibiotics (Mbare) and in MR2 
included villages further from public healthcare facilities. 
The inclusion of households in these areas did not follow 
predefined demographic criteria, but we sought to itera-
tively capture a range of livelihoods and points of access 
to medicines and care in these settings. The AMIS surveys 
(UU and UR) were not attached to a clinical study and 
used the same sampling strategy as the smaller FIEBRE 
surveys within defined study areas in Uganda.
Surveys were conducted by postgraduate researchers 
and/or experienced research assistants. The questions 
asked of respondents were tailored towards each project’s 
aims, with AMIS seeking to understand the roles of anti-
biotics in lives, livelihoods and society more broadly, and 
FIEBRE more specifically focused on the relationship 
between febrile illness and antibiotic use. These differ-
ences aside, surveys commonly included questions about 
household context and demographics, acute illnesses 
frequently experienced by household members, medi-
cines (including antibiotics) used to treat these common 
illnesses and challenges associated with accessing medi-
cines and care. These core domains form the basis of the 
analysis we present here.
In asking households about antibiotics specifically, all 
surveys used a ‘drug bag’ method that we developed, 
methodological reflections of which are published else-
where.11 This involved showing respondents physical 
samples of antibiotics to establish common referents 
with them without assuming that they use biomedical 
categories, both to stimulate deeper conversation within 
the interview itself and to quantitatively identify patterns 
of antibiotic use to be followed up on through further 
ethnographic fieldwork. Drug bags specific to each site 
were assembled by visiting all spaces where antibiotics 
could be acquired locally, including clinics and hospitals, 
retail pharmacies, drug shops, iterant drug sellers and 
market vendors. We included different modes of admin-
istration of the same drug where these existed, but this 
analysis only includes systemic formulations (ie, tablets, 
suspensions and injections, not topical creams or eye 
ointments). All drugs were clearly labelled with packaging 
included, so that respondents were able to recognise the 
drug in a number of different ways, including appear-
ance, generic name and branding. A full breakdown of 
drug bag contents is provided as online supplemental 
material. During the surveys, a series of ‘pile sorting’ 
exercises were conducted to identify which antibiotics 
respondents recognised, had used before, used in the 
month preceding the survey, used ‘frequently’ (as they 
interpreted ‘frequently’) and were unable to access when 
needed (as they interpreted ‘need’). In designing these 
exercises, we avoided asking participants about non- 
prescription use unless they raised the topic themselves, 
to avoid imposing a normative biomedical framework 
that could have made respondents feel judged and thus 
feel reluctant to open up about the many other dimen-
sions of antibiotic use. Quantitative data were produced 
by capturing the contents of the piles, while narrative 
qualitative data were produced through the conversa-
tions stimulated by the process.
Ethnographic fieldwork
The household surveys took place within a broader 
ethnographic methodology that included fieldwork in 
clinics, hospitals, pharmacies, markets and with resi-
dents, as well as with key stakeholders in antimicrobial 
use and resistance. Fieldwork, conducted by anthropol-
ogists, postgraduate researchers and research assistants, 
aimed to gain a deeper understanding of the social, 
economic and health system context of antibiotic use 
profiles identified during the surveys. Following Whyte 
et al’s observation that medicines have social lives analyti-
cally separable from those of human actors,35 our aim was 
to draw out the stories of antibiotics by following them 
as they circulated within and beyond formal healthcare 
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settings in different countries. Households were purpo-
sively sampled for ethnogaphic research from among 
those who expressed interest during surveys. At each site, 
15–25 households were purposively selected to capture 
a range of household contexts and environments. 
Healthcare providers accessible to these households 
were eligible for inclusion, including public, private and 
informal providers. Observation of antibiotic prescribing 
and dispensing took place with a total of 23 providers 
(4 in Malawi, 7 in Zimbabwe and 12 in Uganda). Key 
informants and stakeholders, including individuals with 
relevant knowledge and influence at local, district and 
national levels, were interviewed, totalling 113 over the 
study period (57 in Malawi, 34 in Zimbabwe and 22 in 
Uganda). Ethnographic observation entailed taking part 
in everyday routines, including management of ill health. 
Figure 1 Map showing study settings and population density in Malawi, Uganda and Zimbabwe. Maps were generated 
using ESRI ArcMap 10.8.1 (ESRI 2020; Redlands, California, USA). Population data were sourced from www.worldpop.org and 
consists of 2020 population estimates for each country at the scale of 100 m2 grid cells.
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Interviews followed tailored and regularly updated topic 
guides which drew on findings from other concurrent 
fieldwork activities. The studies in the three countries 
were designed collaboratively between the researchers in 
all three teams, who remained in frequent contact for the 
duration of the fieldwork and analysis to share insights, 
compare findings across sites and add further lines of 
inquiry stimulated by interim analyses.
Patient and public involvement
Participants and stakeholders were engaged throughout 
the research process across all settings. While protocols 
were being developed, key stakeholders were identi-
fied to help to refine research questions and to address 
ethical and logistical challenges; these same individuals, 
some of whom became participants in the research them-
selves, were regularly updated throughout the research 
on findings as they emerged. Preliminary findings were 
also shared with residents and health providers where 
possible, discussions which were iteratively fed back 
into data collection. On completion of data collection, 
findings were disseminated to all participants and stake-
holders, a process which in turn fed back into analysis 
and writing of outputs, including the present article.
Data management and analysis
All data were captured and stored on encrypted devices. 
Data were collected using ODK and transferred to secure 
servers at the London School of Hygiene and Tropical 
Medicine (FIEBRE data) and the Infectious Diseases 
Research Collaboration, Kampala (AMIS data).
Quantitative data, which included quantitative survey 
data and basic prescribing data abstracted from field 
notes with antibiotic providers, was analysed using R.36 
Data were analysed separately according to the protocols 
of each project, and when the concept for this article 
was developed, comparable variables were merged 
into unified dataframes, and descriptive statistics were 
reported for each variable. During the analysis, individual 
antibiotic substances were reclassified into antibiotic 
Table 1 Overview of study settings and healthcare context
Malawi Zimbabwe Uganda
Malawi, a country with a population 
of 17.6 million, is among the poorest 
countries in the world.59 It ranks 174 
out of 189 countries in the human 
development index and had a per capita 
gross national income (GNI) in 2019 of 
$550.60 Malawi gained independence 
from British colonial rule in 1964, with 
Hastings Kamuzu Banda governing the 
country under autocratic rule until 1994. 
He used international donor money for 
large- scale infrastructure projects,61 
often in urban centres leaving rural 
areas underdeveloped. Severe debt, 
limited public sector funds, corruption 
and HIV have undermined modest 
development gains.62–64 Today, the 
majority of funds for public services, 
including health, come from international 
donors.65 Chikwawa is a rural district 
in the country’s southern region, where 
subsistence farming is the predominant 
livelihood. Malaria is endemic and, 
annually, Chikwawa records one of 
the highest rates in Malawi.66 As is the 
case nationally, government health 
services are free, and residents are highly 
reliant on primary facilities.67 However, 
there are geographical inequities in 
healthcare coverage, with rural areas 
facing persistent staff shortages and 
regular medicine stockouts.62 67 Private 
and informal providers exist but are less 
prominent in Chikwawa than in cities, 
partially due to the lack of cash available 
to most residents.
Zimbabwe has a population of 
14.6 million, of which 1.5 million live in the 
capital of Harare. Zimbabwe ranks 150 of 
189 countries in the human development 
index and in 2019 had a per capita GNI 
of $1200.68 Zimbabwe boasted one of 
Africa’s strongest postcolonial healthcare 
systems following independence in 
1980, with robust primary healthcare 
infrastructure and a strong essential 
drugs programme.69 However, by the 
late 1990s, these achievements were 
undone by political repression, structural 
adjustment, hyperinflation, increasing 
privatisation and the HIV pandemic.70 Life 
expectancy was less than 50 years during 
the 2000s, and the neglect of water and 
sanitation infrastructure led to a cholera 
outbreak in 2008–2009 that killed over 
4000 people, many in high- density 
suburbs of Harare.39 Since then, frequent 
and increasingly drug- resistant outbreaks 
of cholera and typhoid have occurred.40 
Mbare and Budiriro, where we conducted 
research, are among such suburbs. 
Most residents live within walking 
distance of a public clinic, yet healthcare 
is not readily accessible: residents 
must pay a user fee and, furthermore, 
must often purchase prescribed 
medicines at a retail pharmacy.50 While 
Zimbabwe has historically had a strong 
regulatory environment, since economic 
collapse, informal markets have grown 
substantially, with Mbare’s expansive 
marketplace a hotspot of medicine 
vending.
Uganda has a large population of 
44.2 million and ranks 159 of 189 in the 
human development index, with a per 
capita GNI in 2019 of $780.71 Before 
independence in 1962, the Ugandan 
health system was entirely funded by 
the government but, following political 
unrest and economic decline in the 
1970s and 80s, during the 1990s health 
sector reforms were implemented, 
including decentralisation, forming a 
multilayered public healthcare system.72 
Healthcare in the public sector in 
Uganda is free but suffers severe 
resources shortages, including frequent 
drug stockouts and a lack of equipment 
and supplies.73 The country’s large 
private sector includes hospitals, clinics, 
pharmacies and drug shops, the latter 
of which are licensed and regulated but 
generally extend beyond their formal 
roles. This includes the unlicensed 
sale of antibiotics.74 Namuwongo is a 
large informal settlement in Kampala, 
where many people who work in the 
city centre and the surrounding affluent 
suburbs reside. The settlement has 
notoriously poor water and sanitation 
infrastructure.75 Nagongera is a 
subcounty in the rural district of Tororo, 
where over 70% of the population 
survive on subsistence farming and 
where most live hand to mouth, with 
over 50% of the population living on 
less than $1 per day.76
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classes and WHO’s AWaRe categories to enable greater 
comparison between sites and to draw out implications 
for stewardship. Qualitative data, which included quali-
tative survey data as well as field notes and interview data 
from the ethnographic phase, were analysed using NVivo 
12. Themes were generated by each country team on an 
iterative basis during which codes of progressively higher 
orders of abstraction were used to explain and theorise 
the data. Comparative analysis was achieved through 
frequent cross- site sharing of findings and discussions 
of themes emerging, with inter- project meetings held 
at least every 2 weeks for the duration of the 3.5- year 
projects.
RESULTS
Demographics and common illnesses
Across all sites, a total of 1811 households participated 
in the household surveys, of which 925 (51.0%) were in 
Malawi, 436 (24.0%) were in Zimbabwe and 450 (24.8%) 
were in Uganda. Demographic characteristics of house-
holds are summarised in table 3. The most common occu-
pations across study settings were labouring (eg, building, 
making, fixing, cleaning or cooking), informal vending 
and subsistence farming, the latter the primary occupation 
of most rural households. Median household size varied 
but was greater in urban areas, with the largest households 
in ZU2 (median: 4). Overcrowding was especially common 
in high- rise flats in Mbare, where several households often 
occupied a single room separated by a divider. The primary 
respondents were predominantly female, ranging from 
56.0% (UR) to 79.0% (ZU2), for various reasons, including 
surveys being conducted during weekday working hours, 
and men often referring our field team to women, who 
were seen to know more about care and medicines, espe-
cially for children. The median age of respondents ranged 
from 27 years (MR1) to 47 years (UR). The most common 
self- reported acute illnesses were colds, flus and coughs, 
but beyond this there were notable differences between 
settings, especially between urban and rural study sites. In 
urban settings, stomach pain and diarrhoea were a more 
regular occurrence likely due to contaminated water 
sources, while in rural areas, where malaria was endemic, 
malaria and fevers were self- reported as the most frequent 
causes of sickness. Households were asked how often they 
were able to get the medicines needed for these illnesses, 
the most common answer to which was ‘sometimes’ (MR1: 
31.2%, ZU1: 58.9%, UU: 13.1%).
Patterns of antibiotic use
The drug bags were a source of considerable curiosity 
wherever we went. With word travelling quickly, surveys 
Table 2 Overview of surveys
Country
Survey 










Malawi MR1 Chikwawa 
district
(rural)
Survey conducted with households of community 
controls who had been randomly matched with 








Targeted survey that included households both in 
same areas as MR1 and in more remote areas of 
Chikwawa, further from public healthcare facilities. 
Selected households followed up ethnographically
100 Purposive




Survey conducted with households of community 
controls who had been randomly matched with 








Targeted survey that included households both in 
same areas as ZU1 and in the dense township of 






Survey in an informal settlement in Kampala, 
conducted as part of AMIS study. Selected 





Survey in a rural town in Tororo district, conducted as 
part of AMIS study. Selected households followed up 
ethnographically
100 Purposive 16
*M, Malawi, Z, Zimbabwe, U, Uganda; 1larger, semi- random survey, 2smaller, purposively sampled survey; R, rural, U, urban.
†The number indicates how many different antibiotic substances were included. Where possible, we also included different modes 
of administration for the same substances to maximise the chances of recognition by respondents; however, these fine- grained 
differences are not explicitly represented in our quantitative analyses to avoid overcomplication. See online supplemental material for 
breakdown of drug bag contents by antibiotic substance and mode of administration.
AMIS, Antimicrobials in Society; FIEBRE, Febrile Illness Evaluation in a Broad Range of Endemicities.
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were usually conducted with several onlookers gathered 
around, attentively watching the pile sorting exercises. 
The main findings regarding patterns of antibiotic use 
are summarised in table 4. Antibiotics were widely recog-
nised by respondents, but this varied considerably within 
and between settings (ranging from a median pile size of 
4 in UR to 7.5 in ZU2). Some antibiotics were especially 
well recognised, the most familiar of which were amoxi-
cillin, doxycycline, cotrimoxazole, metronidazole, cipro-
floxacin, erythromycin and an ampicillin/cloxacillin 
combination drug (the latter only in Uganda). These 
were referred to by short- hand or brand name terms such 
as ‘amoxyl’ (amoxicillin), ‘cotri’ or ‘bactrim’ (cotrimox-
azole), ‘doxy’ (doxycline) and ‘flagyl’ or ‘metro’ (metro-
nidazole). These same antibiotics were most likely to 
have been used before, with a considerable proportion 
of households having used an antibiotic in the last month 
(range: 31.0% in ZU1–71.0% in UR). In Zimbabwe and 
Malawi, most households’ last antibiotic was prescribed at 
a public facility; in Uganda, private providers were more 
commonly used, particularly in Namuwongo (UU).
Aiming to determine which antibiotics featured most 
prominently in everyday life, we were especially inter-
ested in the category of self- reported ‘frequent use’. Most 
households reported frequently using at least one anti-
biotic, with a median of one antibiotic being frequently 
used in ZU1 and MR1 and two in all other surveys. 
Frequent use was heavily concentrated on three drugs—
amoxicillin, cotrimoxazole and metronidazole—all of 
which belong to the WHO Access group. These drugs 
were the three most frequently used antibiotics in 4/6 
surveys (MR1, ZU1, ZU2 and UR) and the remaining two 
surveys (MR2 and UU) had two of these drugs in their 
top three (see table 4). Expressed as a proportion of total 
frequent use (visualised in figure 2), amoxicillin made 
up the greatest proportion (range: 13.5% in UU–53.0% 
in ZU1), followed by cotrimoxazole (range: 8.1% in 
UU–37.9% in MR2) and then metronidazole (range: 
6.1% in MR2–28.5% in UU). Across all our surveys, a 
greater proportion of households were frequently using 
one or more antibiotics from the Access group (range: 
68.8% in ZU1–94% in UR) than from the Watch group 
Table 3 Household context, common illnesses and medicines availability
Variable
Malawi Zimbabwe Uganda
MR1 MR2 ZU1 ZU2 UU UR
Total 
households (n)
  825 100 336 100 350 100
Setting Urban/rural Rural Rural Urban Urban Urban Rural
Primary 
respondent
Age (median, range) 
(years)
27 (18–77) 42 (18–78) 29 (18–71) – – 47 (18–87)
Sex (n, % female) 645 (78.1) 58 (58.0) 243 (72.3) 79 (79.0) 256 (73.1) 56 (56.0)
Household Occupants (median, 
range)
3 (1–13) – 2 (1–13) 4 (1–12) – –
Primary 
occupation
Farmer (n, %) – 82 (82.0) – 2 (2.0) 10 (2.9) 89 (89.0)
Merchant/vendor (n, %) – 9 (9.0) – 57 (57.0) 127 (36.3) 1 (1.0)
Labourer (n, %) – 7 (7.0) – 15 (15.0) 30 (8.6) 1 (1.0)





Cold/flu (n, %) 67 (8.1) 5 (5.0) 252 (75.0) 65 (65.0) 270 (77.1)† 41 (41.0)†
Malaria (n, %) 609 (73.8) 80 (80.0) 39 (11.6) 2 (2.0) 160 (45.7) 77 (77.0)
Cough (n, %) 410 (49.7) 37 (37.0) 177 (52.7) 26 (26.0) –† –†
Stomach pain (n, %) 128 (15.5) 23 (23.0) 220 (65.4) 40 (40.0) 12 (3.4) 19 (19.0)






















Usually (n, %) 297 (36.0) 39 (11.6) 0 (0.0)
Sometimes (n, %) 257 (31.2) 198 (58.9) 46 (13.1)
Rarely (n, %) 125 (15.2) 57 (17.0) 10 (2.9)
Never (n, %) 0 (0.0) 0 (0.0) 0 (0.0)
M, Malawi, Z, Zimbabwe, U, Uganda; 1larger, semi- random survey, 2smaller, purposively sampled survey; R, rural, U, urban.
*Respondents across all three countries generally indicated that medicines were challenging to access for reasons including 
affordability, stockouts and inability to obtain a prescription. Even where medicines were available, this was often at considerable 
expense to the household.
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(range: 8.3% in ZU1–25.0% in ZU2) (see table 4). The 
most frequently used drugs from the Watch group were 
ciprofloxacin, which also belongs to the Access group, 
and erythromycin (figure 2). We observed, however, 
that while frequent use of erythromycin was commonly 
reported in Malawi and this was the third most frequently 
used of all antibiotics in MR2 (table 4), its use seemed 
likely over- reported due to its very similar appearance 
and applications for pain and inflammation to ibuprofen.
With amoxicillin, cotrimoxazole and metronidazole the 
most frequently used antibiotics across all settings, three 
noteworthy features of their patterning prompted partic-
ular ethnographic attention as our research progressed: 
(1) amoxicillin was the most frequently used antibiotic in 
4/6 surveys and in the top 3 in all (table 4), with the anti-
biotic making up the greatest proportion of frequent use 
in ZU1 (53.0%) relative to other surveys (figure 2); (2) 
cotrimoxazole made up a greater proportion of frequent 
use in the Malawian surveys than in other countries (MR1: 
30.0%, MR2: 37.9%) (figure 2); and (3) metronidazole 
made up a greater proportion of frequent use in Uganda 
than in other countries, particularly Namuwongo (UU), 
where it was the most used antibiotic, making up 28.5% 
of all frequent use (figure 2). In the following sections, 
we home in on the biographies35 of these three antibi-
otics in different settings: amoxicillin in Zimbabwe, cotri-
moxazole in Malawi and metronidazole in Uganda. Our 
aim is not to offer a representative analysis of antibiotic 
use in these countries, but to highlight both particular 
and cross- cutting features of health systems and supply 
chains that shape the use of these antibiotics at house-
hold level and that are pertinent for informing antimi-
crobial stewardship interventions.
Amoxicillin and the gaps in public sector healthcare
During ethnographic fieldwork in primary care clinics 
in Harare, Zimbabwe, nurses often referred to amoxi-
cillin as the ‘drug of choice’. This is because of the drug’s 
centrality to the country’s national treatment guideline 
(EDLIZ), which specified which essential medicines 
should be available on the clinic shelves and how they 
should be used. A broad- spectrum penicillin, amoxicillin 
is crucial to the syndromic management approach taken 
by EDLIZ and is a first- line treatment for a wide range of 
conditions, including pneumonia, sinusitis, otitis media 
and urinary tract infections. In the two clinics in which 
we worked in Mbare and in Buduriro, amoxicillin was the 
most prescribed antibiotic, making up 107/253 (42.3%) 
and 88/258 (33.7%) of observed antibiotic prescriptions, 
respectively. Additionally, we found that consultations 
tended to gravitate around the norm and expectation 
of an antibiotic being given, which we similarly found in 
healthcare facilities in Malawi and Uganda. Because of 
its pervasive use in outpatient settings, amoxicillin was 
perhaps expectedly the most widely recognised and used 
across our household surveys.
Figure 2 Proportion (%) of total ‘frequently used’ antibiotics among households in Malawi (MR1, n=825; MR2, n=100), 
Zimbabwe (ZU1, n=336; ZU2, n=100) and Uganda (UU, n=350; UR, n=100). For a full breakdown, see online supplemental 
material. *Includes all other antibiotic substances in the drug bags. M, Malawi, Z, Zimbabwe, U, Uganda; 1larger, semi- random 
survey, 2smaller, purposively sampled survey; R, rural, U, urban.
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However, stockouts of first- line antibiotics, including 
amoxicillin, were a regular occurrence in all of our study 
settings in Zimbabwe, Malawi and Uganda. In Zimbabwe, 
the situation analysis on AMR attributed stockouts to ‘a 
lack of finances at the national level and fragmented 
funding from donors, which are often interested in 
funding drugs for specific programmes rather than the 
workhorse antimicrobials’.37 As box 1 illustrates, resi-
dents in Zimbabwe like Sisi Betty were accustomed to a 
situation in which, more often than not, all they had to 
show for paying a steep user fee and queuing for hours 
at the clinic outpatient department was a ‘piece of paper’ 
with which to seek an antibiotic themselves. Purchasing 
from a retail pharmacy was, however, often not an option 
due to high medicine costs, driving people towards 
the informal marketplace for medicines. Indeed, with 
experience dictating that the clinic was unlikely to have 
medicines in stock, respondents reported that they were 
increasingly being forced to ‘bypass’ the clinic altogether 
to get the medicines they needed. In this process, resi-
dents used the information and experience available to 
them to source the correct medicine:
At times when a neighbour's child goes to the clinic and 
is given a prescription for a similar disease like flu you can 
just opt to go to the market and buy say amoxyl [sic]. You 
see what the medication the neighbour was told to buy, and 
you go to the market to buy the medication—you avoid 
paying consultation fee at the clinic if you check what 
someone else with the same condition was told to buy. 
The market has almost all the drugs; I buy there. (Grand-
mother, 49, Mbare, respondent in ZU2)
It must be stressed that the informal markets in Harare 
were widely viewed as a last resort, with some having real-
ised that the cost of using a potentially substandard drug 
at the marketplace could eventually be even higher than 
the pharmacy- sourced medicines: ‘$1 for 10 pills when 
you buy from the street as compared with those that cost 
$3 from pharmacy the cost may be low but you end up 
going there a lot of times with no real change’ (female, 
informal food vendor selling mealies, Mbare). Addition-
ally, our surveys suggest that residents reported their last 
antibiotic often to have been received at a clinic (37.6% 
in ZU1) or from a retail pharmacy (36.6% in ZU1). 
However, despite respondents’ observed attempts to be 
responsible medicines users, there was often simply no 
alternative than to use the informal sector given the gaps 
in the public healthcare system.
Cotrimoxazole and the programme landscape of ‘global 
health’
Unlike amoxicillin, an antibiotic that is comparatively 
well funded by international donors is cotrimoxazole. 
In Malawi, as in many LMICs, cotrimoxazole is primarily 
used in the management of HIV, having previously been 
more widely used in outpatient care (much like amox-
icillin). Following WHO guidelines,38 cotrimoxazole 
is prescribed as part of antiretroviral therapy initiation 
and prescribed indefinitely afterwards as prophylaxis 
against opportunistic infections. In Chikwawa, such was 
the scarcity of essential medicines in government health-
care facilities, particularly those further away from the 
district hospital, that the only medicines consistently 
available were those funded by donor programmes. This 
included, most notably, antimalarials, TB medicines and 
HIV- related medicines, including cotrimoxazole. This 
meant that cotrimoxazole was routinely prescribed for 
acute illnesses, regardless of patients’ HIV status, simply 
because it was consistently in stock. Even though in 
Malawi, unlike in Zimbabwe, residents did not have to 
pay for public sector healthcare (table 1), with house-
holds surviving through subsistence farming and with 
almost no access to cash they were more heavily reliant 
on these few donor- funded medicines.
Surveys in Chikwawa revealed that cotrimoxazole 
accounted for a high proportion of household use, 
particularly MR2 which included households in more 
remote villages further from the district hospital. As we 
found, residents knew that febrile illness—an extremely 
common occurrence in this malaria- endemic region—
would mean the prescription of either antimalarials or, if 
the rapid test was negative, cotrimoxazole:
My daughter had fever and general body pain, but she was 
not diagnosed malaria, so she was given cotrimoxazole and 
Panadol (paracetamol). (Female, 32, subsistence farmer, 
MR2)
We always get prescribed [cotrimoxazole] from the hospi-
tal when we go for treatment. (Male, 49, subsistence farm-
er, MR1)
However, given the considerable geographical inequal-
ities in access to government health facilities (table 1), 
accessing healthcare and medications could be expensive 
for many. As the vignette in box 2 shows, central to house-
hold coping and care strategies was a moral economy of 
reciprocity that included the storing and sharing of medi-
cines.28 Catastrophic healthcare costs could be mitigated 
through borrowing medicine to treat acute illness and 
reciprocating at a later date when one had leftover medi-
cine. Securing access to cotrimoxazole could be further 
improved through having a household member or a 
Box 1 Amoxicillin use in Harare, Zimbabwe
Sisi Betty smiled as she quickly recognised and picked up a packet 
of amoxicillin as the first medicine that she recognised from a pile of 
antibiotics from the drug bag. This 35- year- old mother of 3 stayed just 
a street away from the busy marketplace of Mbare where medicines 
were a common sight in the hands of drug vendors. ‘This one, I bought 
very cheap at the market, I got two packets with 20 amoxicillin tablets 
for just a dollar. These days I never go to the clinic, it is a waste of 
time and money. The clinic shelves are empty. You only go there to 
pay for a card to see a nurse who only gives you a paper to go to the 
pharmacy. At the pharmacy, you will find everything but the prices 
there will tell you to go away. To get something, you are forced to buy 
very cheap medicine at the market like what I do. The marketplace is 
now my clinic’. (SM fieldnotes, Mbare, Zimbabwe, June 2018)
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neighbour living with HIV and who thus had a consistent 
supply of the medicine, a practice we also observed during 
ethnographic fieldwork in Uganda and Zimbabwe. The 
centrality of cotrimoxazole to prescribing in Malawi and, 
in turn, to household coping and care strategies stems 
from systemic prioritisation of HIV and malaria at the 
expense of more ‘mundane’ acute illnesses.
Metronidazole and the neglect of disease prevention
One consequence of the positioning of high- priority 
pathogens to be addressed through narrow pharmaceu-
tical solutions is the systematic neglect of disease preven-
tion measures, including water and sanitation infrastruc-
ture. In Namuwongo, Uganda (UU), such infrastructure 
was almost completely absent bar a few fee- for- use public 
latrines that were unaffordable to most and in any case 
were too dirty to use. Residents were forced to use buckets 
or plastic bags for toileting, disposed of in open drainage 
channels or community rubbish piles. Like many urban 
informal settlements globally, Namuwongo was portrayed 
in the media as an ‘illegal slum’ that was criminally inhab-
ited. Thus, there was little more than sporadic political 
will to tackle these issues and, as a result, diarrhoea and 
the associated crippling stomach cramps were an almost 
daily occurrence for households. Similar struggles with 
persistent diarrhoea were faced by households in Harare. 
While many occupied legal structures in legitimate areas 
of the city, Harare has long been beset with dilapidated 
water infrastructure, which infamously caused a cholera 
outbreak in 2008–2009 that caused the deaths of thou-
sands.39 With very little investment in water infrastructure 
since, Harare has experienced recurring and increasingly 
drug- resistant cholera and typhoid outbreaks to the 
present day.40
Metronidazole is an antibiotic and antiprotozoal drug 
commonly used in the treatment of anaerobic bacte-
rial infections. In clinics in Harare, metronidazole was 
prescribed second only to amoxicillin. While Zimbabwe’s 
national treatment guideline recommends its use only 
for bloody diarrhoea, such was the anxiety of sending 
patients home without antibiotics given the cholera and 
typhoid situation that metronidazole was prescribed for 
almost all gastrointestinal symptoms. Metronidazole 
was widely recognised across our surveys, particularly in 
urban Uganda and Zimbabwe (UU and ZU1), but what 
surprised us was the extent of metronidazole use in 
Namuwongo, where three quarters of households regu-
larly used the drug, in most cases the week preceding 
the survey. As box 3 illustrates, for the residents served 
by health providers like Maria and Martha, metronida-
zole was an essential antibiotic and one that could be 
purchased relatively cheaply and stored at home. Metro-
nidazole made the symptoms, if not completely better, at 
least tolerable, and enabled the residents of Namuwongo 
to continue to get by. Metronidazole can, thus, be seen 
as a ‘quick fix’ for hygiene and productivity, enabling the 
everyday life to go on amid gaping structural inequalities.
DISCUSSION
Recognition of significant increases in antibiotic use in 
LMICs2–6 and its implications for rising AMR has led to 
urgent calls to understand reasons for antibiotic (mis)use, 
especially beyond prescriber settings.8 9 This article presents 
a mixed- methods, multi- country analysis of the patterns of 
and reasons behind household antibiotic use practices in a 
range of rural and urban settings in Malawi, Uganda and 
Zimbabwe. Embedding the use of a ‘drug bag’ survey tool11 
Box 2 Cotrimoxazole use in Chikwawa, Malawi
At 21:00 one night, one of the neighbours called by the compound 
I was staying in. Her child had developed a fever, cough and fast 
breathing. The family I was staying with did not have any medicine 
stored that day. But one of the women in the nearby house gave 
them cotrimoxazole. I called by the next day to understand what 
had happened. The child’s mother narrated that all the local shops 
were closed. She had no money to hire a taxi to take the child to 
the hospital (approximately 8 km away on mostly dirt roads). The 
child’s father was away, and they couldn’t reach him because he 
could not afford a phone. She said her neighbour had given her 10 
cotrimoxazole tablets. She was giving it to the child in the same 
dose they give you at the hospital—two in the morning, afternoon 
and evening. When I called by again, the child was better, and the 
mother decided not to take her to the clinic. She was relieved that the 
child had got better, because paying for transport had an impact on 
the household. They would not be able to afford food for two meals 
that day so they would have to go to bed on empty stomachs. When 
I probed around whether she would need to return the medicine, 
she explained that because it was cotrimoxazole it would be easy to 
replace. She said it was the one drug that the clinic always gives. In 
the household, once the patient is feeling better, she will be able to 
share the leftover dose. (AK fieldnotes, Chikwawa, Malawi, December 
2019)
Box 3 Metronidazole use in Kampala, Uganda
I sat with Maria in her clinic for hours with no patients in sight. She 
told me she had not served any patients since she opened that 
morning. It had been raining all morning and according to Maria 
it was not surprising that she has not received any patients, ‘they 
do not come while it is raining.’ We talk about the flooding further 
down in the settlement during the rainy season. She tells me that 
when she first started living in Namuwongo close to 25 years ago, 
most of the area further downstream was a swamp with papyrus 
vegetation, explaining the flooding that happens when it rains. A few 
weeks back, I had spent some time with Martha, a long- term resident 
and community health worker who told me there had been a lot of 
diarrhoea in the area recently. She knew this because she was selling 
a lot of zinc and ORS that she buys at a subsidised price from an 
NGO that does health promotion and livelihoods improvement work 
within some communities in the country. I wondered if the increased 
diarrhoea was linked to infections from the aftermath of heavy rains 
and flooding that happens in the rainy season. Maria tells me she has 
plans to stock a lot of flagyl (metronidazole) as she expects many 
patients with diarrhoea now that the rains have started. (CN fieldnotes, 
Namuwongo, Uganda, December 2018)
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within an overarching ethnographic methodology, we high-
lighted antibiotics being frequently used—most notably, 
amoxicillin, cotrimoxazole and metronidazole—before 
explaining their use in terms of systemic processes within 
and between settings that often elude attempts at quantifica-
tion. In this discussion, we draw out the significance of our 
findings in relation to existing quantitative and qualitative 
scholarship before using our wide- angle lens to propose a 
decentring of individual behaviour in LMIC antimicrobial 
stewardship frameworks.
Quantitative data produced using the drug bag survey tool 
add to a growing understanding of the local contours of anti-
biotic use within and between study settings. Our findings 
are broadly consistent with Do et al’s multi- country analysis 
of antibiotic use in Africa and Asia, which found that access 
to antibiotics in African locations was generally restricted, 
particularly in Southern Africa.17 As the authors similarly 
observed in South Africa and Mozambique,17 most antibiotic 
use in Zimbabwe and Malawi stemmed from public sector 
prescribing, with use of private pharmacies and informal 
providers often forced by clinic stockouts. In Uganda, antibi-
otics were obtained from a wider range of sources, reflecting 
the country’s large private sector (table 1), yet even in 
this setting most antibiotics were oral antibiotics from the 
WHO’s Access group rather than classes of medicines with 
higher resistance potential that are to be used Watchfully.19 
Our finding that antibiotic use was heavily concentrated on 
a limited number of Access group medicines across all our 
surveys is well supported in the literature. Amoxicillin, cotri-
moxazole and/or metronidazole have been found to be the 
most widely used antibiotics by several multi- country surveys 
in African settings, including that by Vialle- Valentin et al in 
The Gambia, Ghana, Kenya, Nigeria and Uganda,13 Padget 
et al in Senegal and Madagascar,41 and Fink et al in Malawi, 
Namibia, Senegal, Tanzania and Uganda.14 In short, our 
quantitative data form part of a broader emerging picture 
in Africa of generally restricted antibiotic use with a public 
sector bias, predominated by use of a small number of first- 
line antibiotics.
In addition to the quantitative data produced during 
surveys, our analysis extends to in- depth ethnographic data 
that enable us to tell the stories of the most widely used 
antibiotics.35 Our findings add to a small but growing body 
of work that locates antibiotic use as emergent of political 
and economic structures and systems, thereby decentring 
behaviour as the focal point of antibiotic use trends.42 The 
amoxicillin stories showed both the centrality of antibi-
otics to outpatient care and their persistent under- funding 
in LMICs not only by national governments but also the 
northern donors on whom public sector care in many 
LMICs has been rendered dependent. Thus, residents like 
Sisi Betty in Harare, Zimbabwe, were forced toward the 
informal sector in the frequent occurrence that this drug 
was out of stock. If amoxicillin is the story of under- funded 
public sector healthcare, cotrimoxazole is the story of that 
which has come to fill the gap: an antibiotic funded simply 
by virtue of its relationship to a ‘big’ disease like HIV.43 That 
public sector healthcare and household coping strategies 
alike in rural Malawi gravitate around this old antibiotic 
known to have limited efficacy44 can be read as a residual 
consequence of the more dramatic and widely documented 
‘therapeutic citizenships’45 enacted by northern- funded 
donor programmes in Africa. Finally, the heavy reliance on 
metronidazole among residents of Namuwongo, Uganda, 
represents the story of what has been lost in the turn towards 
increasingly pharmaceuticalised forms of care: the older 
public health emphasis on disease prevention in the form 
of improved hygiene and sanitation infrastructure. While 
some aspects of these stories are particular to each setting, 
they also point toward deep- seated, transnational issues that 
many are aware of but that tend to get back- grounded in 
the practice of global health.46–48 With much at stake in the 
allocation of risk and responsibility for rising rates of AMR 
globally,25 49 making explicit connections between the use of 
antibiotics at household level and their entanglement within 
wider national and transnational systems has arguably never 
been more important.
Our data prompt questions about how antibiotic use 
data can inform AMR policy. Commentators have warned 
of a vicious cycle of surveillance and decision- making that 
results in the imposition of interventions to restrict and 
correct antibiotic use that may not be appropriate or a high 
priority in LMIC settings, including education and aware-
ness campaigns, prescribing audits and formulary restric-
tions.50–52 These risks may be mitigated with more situated 
research and interpretation of data. There has been an 
increase in surveillance capacity in many LMICs to under-
stand local use and resistance profiles, some of which is sensi-
tive to socioeconomic and political factors driving high and 
rising antibiotic use and resistance.3 14 53 However, the epide-
miological technologies and rationalities underpinning the 
majority of research and surveillance on which interven-
tions are based—even those acknowledging wider structural 
factors—has tended to centre the behaviour of end users, 
aiming to factorialise and predict ‘misuse’ by different 
demographic groups. Our research demonstrates the need 
to decentre human behaviour and bring to the fore the 
systemic reasons for antibiotic use. This may be challenging, 
given the comparatively greater availability of expertise and 
templates for understanding and responding to antibiotic 
use through a knowledge–attitudes–practices lens.54 55 This 
challenge is compounded by a lack of resources and support 
in LMICs to develop and implement national action plans.51 
This underscores the need for embedded social research 
expertise in AMR policy and programme implementation 
roles.
How might antibiotic stewardship decentre human 
behaviour? Following a growing number of commentators 
advocating for stewardship frameworks that extend beyond 
behaviour,51 54–56 we propose that it is systems, not individuals, 
that should be considered stewards of antibiotics. This is not 
a new or especially radical proposition; successful steward-
ship programmes in high- income countries rely on multiple 
resource and organisational components.57 However, these 
do not easily travel, and systems for supporting stewardship 
in LMICs will need to be constructed in response to local 
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scenarios. As a first step, more sophisticated methods and 
metrics for knowing antibiotic use in context are needed. 
Our mixed- methods approach grounded in the drug bag 
survey tool and following antibiotics beyond the moment of 
use represents one among a growing number of research 
and surveillance protocols that produce both granular user- 
level data and connect use profiles to the deployment of 
antibiotics by the systems that are entrusted to deliver medi-
cines and care.8 11 51 Such a wide- angle lens in turn expands 
possible pathways for interventions to include those that are 
‘structural’ or ‘AMR sensitive’—for example, health system 
strengthening, infrastructural improvements and poverty 
alleviation strategies—which may be expensive in the 
short term but more cost- effective in the longer term.32 33 
We further contend the importance of attending to trans-
national dynamics between global north and south as part 
of stewardship frameworks. Taking systems as stewards seri-
ously means stepping outside the entrenched ‘grooves’ 
within which we collectively have come to operate and to 
design- out our reliance on antibiotics (and narrower tech-
niques for evaluating their use) from the architecture of 
global healthcare.42 50 This is a tremendous challenge and 
will require bold interdisciplinary collaborations, including 
the emerging field of implementation science58 to develop 
stewardship strategies for particular LMICs. However, this 
is far more likely than narrow behavioural approaches 
to result in sustainable reductions in use both within and 
beyond formal prescriber settings.
The approach taken in this analysis had several limita-
tions. First, our household surveys used purposive and 
semi- random sampling techniques which limit the general-
isability of findings to wider populations. The quantitative 
findings, however, are consistent with other research in sub- 
Saharan Africa,13 14 17 and this approach enabled us to follow 
a more in- depth analysis of antibiotic stories. The drug bags 
were time and resource intensive to assemble and imple-
ment and, particularly as part of an overarching ethno-
graphic methodology, may not be feasible to implement in 
the context of routine surveillance, although elsewhere we 
have considered ways in which the drug bag tool could be 
used to generate representative data with fewer resources.11 
Finally, working with different protocols in each country 
meant that some data, for instance, regarding household 
demographics, were collected differently or not at all for 
each dataset, limiting some of the comparability across 
different studies. At the same time, however, the combined 
analysis did not happen retrospectively; conducted within 
the same anthropology of AMR research group, social 
scientists in the FIEBRE and AMIS teams met fortnightly to 
compare, contrast and collectively learn from experiences 
in different settings. This both strengthened the immer-
sive, single- site ethnographic studies of each country team 
and became the cornerstone of our cross- country analysis 
here. It further generated opportunities for forging not 
only north–south but also south–south connection and 
collaboration.
CONCLUSION
This article presented a mixed- methods, multi- country anal-
ysis of household antibiotic use. Drawing on survey and 
ethnographic data from Zimbabwe, Malawi and Uganda, the 
stories presented of the three most widely used antibiotics—
amoxicillin, cotrimoxazole and metronidazole—illustrate 
cross- cutting characteristics and omissions of the national 
and transnational systems that are entrusted to deliver medi-
cines and care. Our findings challenge the predominant 
focus of current stewardship frameworks on restrictive and 
corrective interventions aimed at antibiotic end users. We 
suggest future strategies could consider systems—not indi-
viduals—as stewards of antibiotics, reducing the need to rely 
on these medicines to fix other issues of inequity, produc-
tivity and security.
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